Therapy with proteolytic enzymes in rheumatic disorders

BioDrugs

Volumn 15, Issue 12, 2001, Pages 779-789

  Leipner, Jörg ^a   Iten, Felix ^a   Saller, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BROMELAIN; CHYMOTRYPSIN; PAPAIN; PLANT EXTRACT; PROTEINASE; TRYPSIN;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG USE; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE;

EID: 0036175469     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115120-00001     Document Type: Review

References (46)

1. Bromelain
2. Medicinal and magical plants in the northern Peruvian Andes
3. Evolutionary families of peptidases
4. The cysteine proteinases of the pineapple plant
5. Isolation and partial characterization of basic proteinases from stem bromelain
6. The medical uses of proteolytic enzymes
7. Anti-inflammatory action of proteolytic enzymes of animal vegetable or bacterial origin administered orally compared with that of known anti-phlogistic compounds
8. Anti-inflammatory actions of proteases, bromelain, trypsin and their mixed preparation
9. Sequential effects of an oral enzyme combination with rutosid in different in vitro and in vivo models of inflammation
10. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis
11. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis
12. α2-macroglobulin-proteinase complexes as correlated with α1-proteinase inhibitor-elastase complexes in synovial fluids of rheumatoid arthritis patients
13. Predominant role of neutrophils in the inactivation of α2-macroglobulin in arthritic joints
14. Effect of antirheumatic drugs on cathepsin B1 from bovine spleen
15. Matrix metalloproteinases, but not cathepsin B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity
16. Effects of an oral enzyme preparation, Chymoral®, upon serum proteins associated with injury (acute phase reactants) in man
17. Action of trypsin: Chymotrypsin (Chymoral forte DS) preparation on acute-phase proteins following burn injury in humans
18. Prevention of murine EAE by oral hydrolytic enzyme treatment
19. Divergent T-cell cytokine patterns in inflammatory arthritis
20. The efficacy of systemic enzyme therapy in the treatment of rheumatoid arthritis
21. Spreading of T-cell autoimmunity of cryptic determinants of an autoantigen
22. Biology of disease. Cytokine binding and clearance properties of proteinase-activated α2-macroglobulins
23. Effects of oral enzymes in collagen II induced arthritis in mice
24. Circulating immune complexes and complement fragment iC3b in chronic polyarthritis during 12 months therapy with oral enzymes in comparison with oral gold
25. Enzyme therapy in comparison with immune complex determinations in chronic polyarthritis
26. Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus diclofenac
27. Short-term treatment of painful osteoarthritis of the knee with oral enzymes: A randomised, double-blind study versus diclofenac
28. Phlogenzym in der behandlung der periarthropathia humeroscapularis tendopathica simplex
29. Results of a double-blind, randomized comparative study of Wobenzym-placebo in patients with cervical syndrome
30. Therapie mit nichtsteroidalen antiphlogistika versus einem oralen enzymkombinationspräparat